HCC: Where Does HCV Therapy Play a Role?
详细信息    查看全文
  • 作者：Stacey Prenner ; Laura Kulik
  • 关键词：Hepatocellular carcinoma ; Hepatitis C ; Cirrhosis ; Direct ; acting antivirals ; Sustained virologic response ; Primary prevention of hepatocellular carcinoma ; Hepatocellular carcinoma surveillance
  • 刊名：Current Hepatitis Reports
  • 出版年：2016
  • 出版时间：March 2016
  • 年：2016
  • 卷：15
  • 期：1
  • 页码：17-25
  • 全文大小：313 KB
  • 参考文献：1.Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013.
    2.Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.PubMedCentral CrossRef PubMed
    3.Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.CrossRef PubMed
    4.El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–75.PubMedCentral CrossRef PubMed
    5.Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43:66–72.CrossRef PubMed
    6.••
Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54. These are the current guidelines for HCV treatment with the new direct-acting antivirals. These guidelines also identify which patients need continued surveillance for HCC after successful treatment. CrossRef
7.Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008. Hepatology. 2012;55:476–82.CrossRef PubMed
8.Hsu YC, Wu CY, Lin JT. Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma. Semin Oncol. 2015;42:329–38.CrossRef PubMed
9.Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology. 2012;142:1274–8.PubMedCentral CrossRef PubMed
10.Benvegnu L, Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci. 1996;41:49S–55.CrossRef PubMed
11.Zemel R, Gerechet S, Greif H, Bachmatove L, Birk Y, Golan-Goldhirsh A, et al. Cell transformation induced by hepatitis C virus NS3 serine protease. J Viral Hepat. 2001;8:96–102.CrossRef PubMed
12.McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene. 2011;30:1969–83.PubMedCentral CrossRef PubMed
13.Street A, Macdonald A, McCormick C, Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. J Virol. 2005;79:5006–16.PubMedCentral CrossRef PubMed
14.Milward A, Mankouri J, Harris M. Hepatitis C virus NS5A protein interacts with beta-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion. J Gen Virol. 2010;91:373–81.CrossRef PubMed
15.Aoki H, Hayashi J, Moriyama M, Arakawa Y, Hino O. Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. J Virol. 2000;74:1736–41.PubMedCentral CrossRef PubMed
16.Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–48.PubMedCentral CrossRef PubMed
17.Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case–control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005;92:607–12.PubMedCentral CrossRef PubMed
18.Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75:347–54.CrossRef PubMed
19.Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–5.CrossRef PubMed
20.Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999;29:1870–5.CrossRef PubMed
21.Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnu L, et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology. 1999;46:3216–22.PubMed
22.Azzaroli F, Accogli E, Nigro G, Trere D, Giovanelli S, Miracolo A, et al. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol. 2004;10:3099–102.CrossRef PubMed
23.Soga K, Shibasaki K, Aoyagi Y. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatogastroenterology. 2005;52:1154–8.PubMed
24.Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A. 1995;92:4562–6.PubMedCentral CrossRef PubMed
25.Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer. 2011;129:1254–64.CrossRef PubMed
26.Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011;140:1990–9.CrossRef PubMed
27.Afdhal NH LR, Brown RJ, et al. Colchicine versus peg-interferon alfa 2b long-term therapy: results of the 4 year COPILOT trial. In: 43rd Annual Meeting of the European Association for the Study of the Liver; 2008; Milan, Italy; 2008.
28.Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429–41.PubMedCentral CrossRef PubMed
29.Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11:985–94.PubMed
30.Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–8. 288 e281.CrossRef PubMed
31.Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:923–30.CrossRef PubMed
32.Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889–900.CrossRef PubMed
33.••
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37. This is one of the more recent meta-analyses looking at the effect of primary prevention of HCC through viral eradication of HCV. CrossRef PubMed
34.Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012;67:2766–72.CrossRef PubMed
35.Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–22.CrossRef PubMed
36.Huang CF, Yeh ML, Tsai PC, Hsieh MH, Yang HL, Hsieh MY, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol. 2014;61:67–74.CrossRef PubMed
37.Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015;121:2874–82.CrossRef PubMed
38.Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40:148–56.CrossRef PubMed
39.Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57:964–73.CrossRef PubMed
40.Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, et al. Post-treatment levels of alpha-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12:1186–95.CrossRef PubMed
41.Yamashita N, Ohho A, Yamasaki A, Kurokawa M, Kotoh K, Kajiwara E. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol. 2014;49:1504–13.CrossRef PubMed
42.•
Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015;30:1183–9. This study showed that patients who achieve SVR are less likely to have sequelae of portal hypertension. CrossRef PubMed
43.Chang KC, Tseng PL, Wu YY, Hung HC, Huang CM, Lu SN, et al. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clin Gastroenterol Hepatol. 2015;13:1017–24.CrossRef PubMed
44.Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer. 2011;128:2344–52.CrossRef PubMed
45.Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132–41.CrossRef PubMed
46.Lee HW, Chon YE, Kim SU, Kim BK, Park JY, Kim DY, et al. Predicting liver-related events using transient elastography in chronic hepatitis C patients with sustained virological response. Gut Liver. 2015. doi:10.​5009/​gnl15021 .
47.Taniki NEH, et al. The usefulness of non-invasive liver stiffness measurement by Fibroscan® for risk management of HCC in chronic hepatitis C patients who achieved sustained virological response (SVR). In: Boston, MA: AASLD; 2014.
48.Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44–57.CrossRef PubMed
49.Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587–96.CrossRef PubMed
50.OPTN. Revised liver policy regarding HCC exception scores. 2015. https://​optn.​transplant.​hrsa.​gov/​news/​revised-liver-policy-regarding-hcc-exception-scores/​ .
51.Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373–82.PubMedCentral CrossRef PubMed
52.Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.CrossRef PubMed
53.Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, et al. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. J Clin Oncol. 2013;31:766–73.CrossRef PubMed
54.Liu WR, Tian MX, Jin L, Yang LX, Ding ZB, Shen YH, et al. High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads. Ann Surg Oncol. 2015;22:843–50.CrossRef PubMed
55.Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89:418–22.CrossRef PubMed
56.Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–32.CrossRef PubMed
57.Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.CrossRef PubMed
58.Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299–306.CrossRef PubMed
59.Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, et al. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology. 2012;59:529–32.PubMed
60.•
Singal AK, Freeman Jr DH, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851–8. This meta-analysis was the most recent to look at secondary prevention of HCC. It looked at patients who received definitive treatment for HCC with either ablation or resection, showing that those who achieve SVR have fewer recurrences. CrossRef PubMed
61.van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.CrossRef PubMed
62.McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L’Italien G, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014;174:204–12.CrossRef PubMed
63.Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135:821–9.CrossRef PubMed
64.Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–87.CrossRef PubMed
65.•Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–44. This study evaluated patients in the HALT-C trial and showed that those who achieved SVR had a lower rate of liver transplantation and overall mortality. PubMedCentral CrossRef PubMed
66.Lens S, Rincon D, Garcia-Retortillo M, Albillos A, Calleja JL, Banares R, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol. 2015;13:1846–53. e1841.CrossRef PubMed
67.Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495–503.CrossRef PubMed
68.AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://​www.​hcvguidelines.​org . Accessed January 12, 2016.
69.Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815–20.CrossRef PubMed
70.Horster S, Bauerlein FJ, Mandel P, Raziorrouh B, Hopf C, Stemmler HJ, et al. Influence of hepatitis C virus infection and high virus serum load on biliary complications in liver transplantation. Transpl Infect Dis. 2013;15:306–13.CrossRef PubMed
71.Everson GT, Terrault NA, Lok AS, del Rodrigo R, Brown Jr RS, Saab S, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57:1752–62.PubMedCentral CrossRef PubMed
72.Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117:149–53.CrossRef PubMed
73.Renz JF, Kin C, Kinkhabwala M, Jan D, Varadarajan R, Goldstein M, et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg. 2005;242:556–63. discussion 563–555.PubMedCentral PubMed
74.••Curry MP, Forns X, Chung RT, Terrault NA, Brown Jr R, Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100–7. This study is the only study looking at the effectiveness of the new direct-acting antiviral in patients with hepatocellular carcinoma. CrossRef PubMed
75.Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162:407–19.CrossRef PubMed
76.Verla-Tebit E, Rahma OE. Regression of hepatocellular carcinoma after treatment of hepatitis C: a case report. J Gastrointest Oncol. 2015;6:E52–4.PubMedCentral PubMed
77.Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4:342–59.PubMedCentral CrossRef PubMed
78.ASCO. Nivolumab in HCC and pembrolizumab in tumors with mismatch repair deficiency. In: ASCO Daily News; 2015.
  • 作者单位：Stacey Prenner (1)
    Laura Kulik (1)

    1. Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Arkes Family Pavillion Suite 1900, 676 North Saint Clair Street, Chicago, IL, 60611, USA
  • 刊物主题：Hepatology;
  • 出版者：Springer US
  • ISSN：1541-0706
    • 文摘
    Viral infections have the potential to induce carcinogenesis through chronic inflammation. Hepatitis B and hepatitis C (HCV) are two major risk factors for the development of hepatocellular carcinoma (HCC) and are responsible for 70–80 % of cases seen worldwide. The incidence of HCC has been rising in the USA over the last several decades, largely in part to the prevalence of HCV-induced cirrhosis. Curative therapies with resection and orthotopic liver transplantation are only available for individuals with early-stage HCC, and disease recurrence is still common after treatment, highlighting the need for both primary and secondary preventative measures. Despite the low rates of viral eradication with interferon-based regimens, many studies have shown a chemo-protective effect in patients who do achieve a sustained virologic response. The emergence of new direct-acting antiviral agents with cure rates above 95 % has the potential to change the landscape of HCV-induced HCC. This article discusses the current data for HCV therapy as a chemo-preventive agent and HCV treatment strategies for patients with various stages of hepatocellular carcinoma.

    © 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

    地址：北京市海淀区学院路29号 邮编：100083

    电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700